期刊文献+

PI3K信号通路及其抑制剂抗恶性肿瘤的研究进展 被引量:8

PI3K signaling pathway and its inhibitors in anti-cancer researches
下载PDF
导出
摘要 磷脂酰肌醇-3-激酶(phosphoinositide 3-kinases,PI3K)介导的信号通路是细胞内重要信号转导通路之一,该通路调节细胞的增殖、分化、凋亡等活动。因此,PI3K被认为与人类的多种恶性肿瘤的发生、发展、转归密切相关。本文对PI3K信号通路的组成、功能及其抑制剂抗恶性肿瘤的研究进展作一综述。
作者 陈正军 黄翔
出处 《实用医院临床杂志》 2011年第3期140-143,共4页 Practical Journal of Clinical Medicine
  • 相关文献

参考文献39

  • 1Osaki M,Oshimura M,Ito H.PI3K-Akt pathway:its functions and alterations in human cancer[J].Apoptosis,2004,9(6):667-676.
  • 2Song G,Ouyang GL,Bao SD.The activation of Akt/PKB signaling pathway and cell survival[J].J Cell Mol Med,2005,9(1):59-71.
  • 3Shultz JC,Goehe RW,Wijesinghe DS,et al.Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-Kinase/Akt pathway via phosphorylation of SRp30a[J].Cancer Res,2010,70(22):9185.
  • 4Gibson EM,Henson ES,Haney N,et al.Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release[J].Cancer Res,2002,62(2):488-496.
  • 5Strano S,Monti O,Pediconi N,et al.The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage[J].Mol Cell,2005,18(4):447-459.
  • 6Zhou X,Tan M,StoneHawthome V,et al.Activation of the Akt/mammalian target of Rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers[J].Clin Cancer Res,2004,10(20):6779-6788.
  • 7Asnaghi L,Bruno P,Priulla M,et al.mTOR:a protein kinase switching between life and death[J].Pharmacol Res,2004,50(6):545-549.
  • 8郭琳,王强.PI3K/Akt/mTOR信号传导通路与恶性肿瘤浸润和转移的研究进展[J].现代肿瘤医学,2009,17(8):1585-1589. 被引量:24
  • 9Douglas AL,Faina B,Cindy JY,et al.Frequent mutation of the PIK3CA gene in ovarian and breast cancer[J].Clin Cancer Res,2005,11(8):2875-2878.
  • 10Michl P,Downward J.Mechanisms of disease:PI3K/AKT signaling in gastrointestinal cancers[J].J Gastroenterol,2005,43(10):1133-1139.

二级参考文献61

  • 1石松长,黄昌明.PI_3K[MS1]/Akt信号通路与消化道肿瘤的研究进展[J].医学综述,2007,13(14):1070-1072. 被引量:5
  • 2Klippel A,Escobedo MA,Wachowicz MS,et al.Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation[J].Mol Cell Biol,1998,18(10):5699-5711.
  • 3Collado M,Medema RH,Garcia-Cao I,et al.Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1[J].J Biol Chem,2000,275(29):21960-21968.
  • 4Graff JR,Konicek BW,McNulty AM,et al.Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression[J].J Biol Chem,2000,275(32):24500-24505.
  • 5Shtivelman E,Sussman J,Stokoe D.A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle[J].Curr Biol,2002,12(11):919-924.
  • 6Mayo LD,Donner DB.A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of mdm2 from the cyto-plasm to the nucleus[J].Proc Natl Acad Sci USA,2001,98(20):11598-11603.
  • 7Henshall DC,Araki T,Schindler CK,et al.Activation of bcl-2 associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death[J].J Neurosci,2002,22(19):8458-8465.
  • 8Xin M,Deng X.Nicotine inactivation of the proapoptotic function of Bax through phosphorylation[J].J Biol Chem,2005,280(11):10781-10789.
  • 9Bartling B,Tostlebe H,Darmer D,et al.Shear stress-dependent expression of apoptosis-regulating genes in endothelial cells[J].Biochem Biophys Res Commun,2000,278(3):740-746.
  • 10Li N,Banin S,Ouyang H,et al.ATM is required for IkappaB kinase (IKKk) activation in response to DNA double strand breaks[J].J Biol Chem,2001,276(12):8898-8903.

共引文献45

同被引文献116

  • 1姜涛,姜辉,宋希双,李宪承,李泉林.前列腺癌中P53的表达及其临床意义[J].中华男科学杂志,2005,11(6):448-451. 被引量:11
  • 2阎洪涛,龚百生,董丹丹,杨红,陈照祥.p53和VEGF在前列腺癌组织中的表达及临床意义[J].现代泌尿外科杂志,2007,12(4):242-245. 被引量:9
  • 3Kazlauskas A, Cooper JA. Phosphorylation of the PDGF receptor beta subunit creates a tight binding site for phosphatidylinositol 3 kinase [ J]. EMBO J, 1990,9 (10) :3279-3286.
  • 4Wee S, Lengauer C, Wiederschain D. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis:implications for cancer drug discovery and development [ J ]. Curr Opin 0ncol,2008,20 (1) :77- 82.
  • 5Eisenreich A, Rauch U. PI3K inhibitors in cardiovascular disease [ J ]. Cardiovasc Ther,2011,29 ( 1 ) : 29-36.
  • 6Hawkins PT, Anderson KE, Davidson K, et al. Signalling through Class I PI3Ks in mammalian cells [ J ]. Biochem Soc Trans ,2006,34 (Pt 5) :647-662.
  • 7Schnell CR, Stauffer F, Allegrini PR, Effects of the dual phosphati-dylinositol 3-kinase/mammalian target of rapamycin inhibitor NVPBEZ235 on the tumor vasculature:implications for clinical imaging [ J ]. Cancer Res ,2008,68 ( 16 ) :6598- 6607.
  • 8Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity [ J ]. Cancer Res,2008,68 ( 1 ) :206-215.
  • 9Miled N, Yan Y, Hon WC, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit [ J ]. Science,2007,317 ( 5835 ) :239-242.
  • 10Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling [ J ]. Ce11,2006,125 (4) :733-747.

引证文献8

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部